iHealthScreen’s Artificial Intelligence (AI) Based Tool Can Accurately Diagnose Age-Related Macular Degeneration (AMD) and Help Prevent Blindness
Prospective Study Presented at the Annual Meeting of the American Academy of Ophthalmology (AAO), November 13-15, 2020.
- Selected for the AAO 2020 panel discussion as one of the outstanding works
- First prospective clinical study on AI and color retinal image based early diagnosis of AMD in outpatient settings
- 88.7% accuracy achieved on 503 fundus images of 299 patients followed-up prospectively
RICHMOND HILL, N.Y.–(BUSINESS WIRE)–iHealthScreen CEO Alauddin Bhuiyan, Ph.D. along with collaborators at New York Eye and Ear Infirmary at Mount Sinai (NYEEI), presented a prospective study for early diagnosis of AMD at the annual conference of AAO, 2020. The results presented during the prestigious Original Paper Session demonstrated 88.7% accuracy, compared to ophthalmologist gradings, on detecting referable AMD.
AMD, with no early signs or symptoms, is a leading cause of adult blindness in the developed world. Early detection can enable preventative measures in time and stop AMD incident. Currently, AMD diagnosis has been limited to retinal examination by an ophthalmologist. AMD cases in the U.S. are expected to grow from 2.1 million to 5.4 million in the next ten years, and there is an increasing need for large scale screening and identification of individuals who are at risk of developing late AMD. iHealthScreen’s AI based tool can facilitate this screening and help prevention of late AMD.
In an interview, Dr. Bhuiyan spoke about the study and the findings: “We are encouraged by the results and believe that the new AI-based technology can diagnose early AMD in primary care settings, which enables the timely preventative measures by ophthalmologist and prevent this deterioration of vision. We want to express our sincerest thanks to the participants and professional staff who were involved in this clinical trial and gathered the data.”
“These results speak to the feasibility of this approach,” said Theodore Smith, M.D., Ph.D., Trial’s Principal-investigator and Professor at Icahn School of Medicine at Mount Sinai. “I believe that the ease of use of iHealthScreen’s AI tool will contribute to its adoption in the wider primary care community.”
iHealthScreen is a private, clinical-stage, medical diagnostic/device company. iHealthScreen has developed iPredict, an AI and telemedicine-based HIPAA compliant platform for automated screening and prediction of individuals at risk of developing late age-related AMD, diabetic retinopathy (DR), glaucoma, cardiovascular heart disease and stroke.
Director of Investor Relations & Corporate Communications, iHealthScreen